Table 4.
Summary of IFN-free direct-acting antivirals for acute HCV infection
| Study (year) | Regimen | Duration (week) | Patient, n | PLWH (%) | PWID (%) | Hemodialysis (%) | HCV GT | SVR12 (%) (ITT) | SVR12 (%) (PP) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical trial | ||||||||||
| DARE-C II (2016) [91] | SOF+RBV | 6 | 19 | 84 | 74 | 0 | 1a (68%) | 32 | 40 | |
| 2b (5%) | ||||||||||
| 3a (21%) | ||||||||||
| 3 (5%) | ||||||||||
| SWIFT-C Cohort-1 (2017) [92] | SOF+RBV | 12 | 17 | 100 | 24 | 0 | 1a (65%) | 59 | 59 | |
| 1b (12%) | ||||||||||
| 1 (12%) | ||||||||||
| 2b (6%) | ||||||||||
| HepNet Acute HCV IV (2017) [93] | SOF/LDV | 6 | 20 | 0 | 0 | 0 | 1a (55%) | 100 | 100 | |
| 1b (45%) | ||||||||||
| Rockstroh et al. (2017) [94] | SOF/LDV | 6 | 26 | 100 | NA | 0 | 1a (73%) | 77 | 88 | |
| 4a/c/d (27%) | ||||||||||
| SWIFT-C Cohort-2 (2017) [95] | SOF/LDV | 8 | 27 | 100 | 19 | 0 | 1a (85%) | 100 | 100 | |
| 1b (14%) | ||||||||||
| 4 (4%) | ||||||||||
| TARGET3D (2018) [96] | PrOD±RBV* | 8 | 30 | 77 | 53 | 0 | 1a (93%) | 97 | 100 | |
| 1b (3%) | ||||||||||
| 1 (3%) | ||||||||||
| DAHHS2 (2019) [97] | EBR/GZR | 8 | 80 | 91 | NA | 0 | 1a (64%) | 94 | 99 | |
| 4 (36%) | ||||||||||
| Martinello et al. (2020) [100] | GLE/PIB | 6 | 30 | 77 | 47 | 0 | 1a (73%) | 90 | 96 | |
| 1b (3%) | ||||||||||
| 1 (7%) | ||||||||||
| 3a (7%) | ||||||||||
| 4d (10%) | ||||||||||
| REACT (2021) [101] | SOF/VEL | 6 | 93 | 70 | 19 | 0 | 1a (62.4%) | 82 | 89 | |
| 1b (4.3%) | ||||||||||
| 1 (1.1%) | ||||||||||
| 3 (16.1%) | ||||||||||
| 4 (16.1%) | ||||||||||
| 12 | 95 | 68 | 22 | 0 | 1a (60.0%) | 91 | 98 | |||
| 1b (2.1%) | ||||||||||
| 2 (4.0%) | ||||||||||
| 3 (17.9%) | ||||||||||
| 4 (15.8%) | ||||||||||
| HepNet Acute HCV V (2022) [102] | SOF/VEL | 8 | 20 | NA | NA | 0 | 1a (60%) | 90 | 100 | |
| 1b (5%) | ||||||||||
| 2 (5%) | ||||||||||
| 3 (15%) | ||||||||||
| 4 (15%) | ||||||||||
| Real-world study | ||||||||||
| Chromy et al. (2019) [109] | SOF/LDV | 12 | 38 | 100 | 0 | 0 | 1a (66%) | 100 | 100 | |
| SOF/VEL | 1b (11%) | |||||||||
| PrOD | 2 (3%) | |||||||||
| PrO | 3 (13%) | |||||||||
| EBR/GZR | 4 (8%) | |||||||||
| GLE/PIB | ||||||||||
| Hussein et al. (2019) [110] | SOF+DCV† | 12 | 17 | 0 | 0 | 100 | 1a (100%) | 100 | 100 | |
| SOF/LDV | 12 | 2 | 0 | 0 | 100 | 1a (100%) | 100 | 100 | ||
| He et al. (2018) [111] | SOF+DCV† | 24 | 33 | 0 | 0 | 100 | 1b (21%) | 100 | 100 | |
| 2a (72%) | ||||||||||
| 1b+2a (6%) | ||||||||||
| Goel et al. (2021) [112] | SOF+DCV† | 8 | 27 | 0 | 0 | 100 | 1 (22%) | 93 | 96 | |
| 3 (37%) | ||||||||||
| 4 (7%) | ||||||||||
| Not tested (33%) | ||||||||||
| Ji et al. (2022) [113] | EBR/GZR | 12 | 68 | 0 | 0 | 100 | 1b (100%) | 100 | 100 | |
IFN, interferon; HCV, hepatitis C virus; PLWH, people living with human immunodeficiency virus; PWID, people who inject drugs; GT, genotype; SVR12, sustained virologic response at off-therapy week 12; ITT, intention-to-treat; PP, per-protocol; SOF, sofosbuvir; RBV, ribavirin; LDV, ledipasvir; PrOD, paritaprevir/ritonavir/ombitasvir plus dasabuvir; EBR, elbasvir; GZR, grazoprevir; GLE, glecaprevir; PIB, pibrentasvir; VEL, velpatasvir; DCV, daclatasvir.
*
PrOD for HCV GT1, PrOD plus RBV for HCV GT1a, or unsubtypable GT1.
†
Daily dose of SOF was 200 mg.